FILTER
FILTERED INTERVIEW RESULTS
Alan Seem
PARTNER, JONES DAY
Jones Day is the largest law firm in the United States and one of the ten largest firms globally.
David Craford
PRESIDENT AND CEO, CYTOBANK
Cytobank is developing and commercializing the leading SaaS platform for machine learning-based analysis of high-complexity life sciences data.
Paul Tanico
CEO, NEURODIAGNOSTICS LLC
NeuroDiagnostics is focused on its DISCERN™ test for the diagnosis of Alzheimer’s disease.
Kevin Grimes
CO-DIRECTOR, SPARK TRANSLATIONAL RESEARCH PROGRAM, STANFORD UNIVERSITY
The Stanford SPARK program was established in 2006 to advance new biomedical research discoveries into promising new treatments for patients.
Louis Lehot
MANAGING PARTNER, DLA PIPER
DLA Piper, one of the largest law firms in the world, has a footprint across 40 juris-dictions and an active life sciences sector team.
Eugene Williams
EXECUTIVE CHAIRMAN, PROMIS
ProMIS Neurosciences is a development-stage biotech company focused on neurodegenerative diseases, particularly Alzheimer’s disease and ALS.
Wu Yifang
CEO, FOSUN PHARMA
Fosun Pharma is a leading pharma company in China with innovative and global ambitions.
Sara Radcliffe
PRESIDENT & CEO, CALIFORNIA LIFE SCIENCES ASSOCIATION
California Life Sciences Association (CLSA) is the trade association representing California’s in-novative life sciences industry, ensuring that it retains its competitive edge.
Dr. Jim Li
CEO, SUNDIA
Sundia is a CRO based in China and speaks to GBR of the evolution of the drug discovery process in China.
Dr. Xu Jia
CONSULTING LEADER, PWC CHINA HEALTHCARE AND PHARMACEUTICALS
PwC in China is benefitting from the rise of the biopharma and a flurry of IPO and acquisition activities in the pharma industry more generally.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2024 - Digital Interactive
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
